Page last updated: 2024-12-05

toluene 2,4-diisocyanate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Toluene 2,4-Diisocyanate: Skin irritant and allergen used in the manufacture of polyurethane foams and other elastomers. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

toluene 2,4-diisocyanate : A toluene meta-diisocyanate in which the isocyanato groups are at positions 2 and 4 relative to the methyl group on the benzene ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11443
CHEMBL ID1086446
CHEBI ID53556
SCHEMBL ID15384
MeSH IDM0021639

Synonyms (125)

Synonym
17x7afz1gh ,
unii-17x7afz1gh
ec 209-544-5
STL301891
2,4-diisocyanatotoluene
2,4-diisocyanato-1-methylbenzene
di-iso-cyanatoluene
toluene-2,4-diisocyanate
benzene,4-diisocyanato-1-methyl-
tolueen-diisocyanaat
2,4-tdi
4-methyl-m-phenylene isocyanate
2,4-toluene diisocyanate
584-84-9
4-methyl-m-phenylene diisocyanate
nci-c50533
nsc4791
tolylene-2,4-diisocyanate
toluylene-2,4-diisocyanate
tuluylendiisocyanat
diisocyanat-toluol
di-isocyanate de toluylene
toluene 2,4-diisocyanate
TDI ,
2,4-tolylene diisocyanate
isocyanic acid, 4-methyl-m-phenylene ester
toluilenodwuizocyjanian
isocyanic acid, methylphenylene ester
tolylene 2,4-diisocyanate
wln: ocnr b1 enco
toluen-disocianato
toluene diisocyanate
nsc-4791
toluene diisocyanate, commercial grade (2,4 (80%)- and 2,6 (20%)-)
nsc56759
nsc-56759
inchi=1/c9h6n2o2/c1-7-2-3-8(10-5-12)4-9(7)11-6-13/h2-4h,1h
benzene, 2,4-diisocyanato-1-methyl-
NCGC00091095-01
mondur td-80
diisocyanatomethylbenzene
toluen-disocianato [italian]
tolyene 2,4-diisocyanate
toluene, 2,4-diisocyanato-
desmodur t80
ccris 3742
nsc 56759
hylene t
einecs 209-544-5
brn 0744602
hsdb 874
nacconate ioo
diisocyanat-toluol [german]
tuluylendiisocyanat [german]
nsc 4791
di-isocyanate de toluylene [french]
mondur tds
toluilenodwuizocyjanian [polish]
rcra waste number u223
cresorcinol diisocyanate
tolylene diisocyanate
tolueen-diisocyanaat [dutch]
tdi-80
ai3-15101
rubinate tdi 80/20
mondur td
hylene tlc
2,4-diisocyanato-1-methylbenzene [toluenediisocyanates]
tolylene-2,4-diisocyanate, 95%
tolylene-2,4-diisocyanate, technical grade, 80%
NCGC00091095-02
2,4- & 2,6-toluene diisocyanate
2,4-toluenediisocyanate
toluene 2,4-diisocyanate, purum, for electron microscopy, >=98.0% (gc)
2,4-toluylene diisocyanate
toluene-2,4-diyl diisocyanate
CHEBI:53556 ,
T0263
4-methyl-1,3-phenylene diisocyanate
CHEMBL1086446 ,
bdbm50318488
AKOS000119430
A831895
2,4-diisocyanato-1-methyl-benzene
NCGC00091095-03
NCGC00091095-05
NCGC00091095-04
benzene, diisocyanatomethyl-
1321-38-6
NCGC00259607-01
NCGC00257698-01
tox21_300160
dtxcid901361
dtxsid7026156 ,
cas-584-84-9
tox21_200144
dsstox_rid_77374
tox21_202058
dsstox_gsid_24341
NCGC00253965-01
dsstox_cid_1361
cas-26471-62-5
26006-20-2
EPITOPE ID:115138
4-methyl-m-phenylene ester
SCHEMBL15384
toluene diisocyanate, 2,4-
toluene 2,4-di-isocyanate
toluene 2,4-diisocyanate [mi]
nacconate 100
2,4-diisocyanate
toluene 2,4-diisocyanate [hsdb]
tolylenediisocyanate
2,4-tolylenediisocyanate
hylene tm-65
hylene tcpa
hylene trf
hylene tm
mfcd00002011
2,4-tdi, analytical standard
toluene-2,4-diisocyanate, tech. 80%
Q415183
BS-44197
EN300-20220
Z104477324

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" When the ratio of functional side chain to bis-GMA is increased, the stereo hindrance of resin structure is increased, more toxic resin monomers are trapped in the complicated resin structure, and thus the resin matrix reveals less cytotoxicity."( Biocompatibility and cytotoxicity of two novel low-shrinkage dental resin matrices.
Jan, YD; Lee, BS; Lin, CP; Tseng, WY, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" In order to establish dose-response relationships and determine host factors, complete biologic monitoring, including pulmonary function and immunologic studies, has been performed concurrently with a comprehensive environmental monitoring program including continuous sampling for atmospheric concentrations of TDI."( Respiratory effects in toluene diisocyanate manufacture: a multidisciplinary approach.
Butcher, B; Neilson, A; Salvaggio, J; Weill, H; Ziskind, M, 1975
)
0.25
" Dose-response curves were obtained by utilizing the maximum percent decrease in respiratory rate as the response parameter during each exposure."( Sensory irritation and incapacitation evoked by thermal decomposition products of polymers and comparisons with known sensory irritants.
Alarie, Y; Barrow, CS; Stock, MF,
)
0.13
" Blood samples obtained prior to and at various times after PIC were used to measure complement and split products of complement and plasma histamine levels and to determine dose-response slopes of lymphocyte cyclic adenosine monophosphate (cAMP) following stimulation with agonists."( Inhalation challenge and pharmacologic studies of toluene diisocyanate (TDI)-sensitive workers.
Butcher, BT; Dharmarajan, V; Karr, RM; O'Neil, CE; Salvaggio, JE; Weill, H; Wilson, MR, 1979
)
0.26
" To determine whether a calibrated dosage of oral slow-release theophylline inhibits asthmatic reactions and the associated increase of airway responsiveness to methacholine induced by TDI, we examined six asthmatic subjects who developed a late or a dual asthmatic reaction after TDI inhalation challenge."( Theophylline inhibits late asthmatic reactions induced by toluene diisocyanate in sensitised subjects.
Boschetto, P; Ciaccia, A; Crescioli, S; De Marzo, N; Fabbri, LM; Mapp, CE; Plebani, M; Spinazzi, A, 1992
)
0.28
" Greater than 10% depression in body weight gain occurred in all dosed groups of rats throughout most of the study."( The carcinogenic activity of commercial grade toluene diisocyanate in rats and mice in relation to the metabolism of the 2,4- and 2,6-TDI isomers.
Boorman, GA; Dieter, MP; Huff, JE; Jameson, CW; Matthews, HB, 1990
)
0.28
"Little epidemiological data are available to enable the development of a dose-response relationship for the effects of isocyanates, powerful sensitizing agents in humans."( Setting acceptable exposure limits for toluene diisocyanate on the basis of different airway effects observed in animals.
Borm, PJ; Henderson, PT; Jorna, TH, 1990
)
0.28
" However, phosphoramidon caused a significantly greater leftward shift of the substance P dose-response curve in air-exposed animals than it did in TDI-exposed animals, so that after phosphoramidon, mean values of PD200 in animals exposed to air or TDI did not differ."( Toluene diisocyanate increases airway responsiveness to substance P and decreases airway neutral endopeptidase.
Borson, DB; Dusser, D; Nadel, JA; Scypinski, L; Sheppard, D; Thompson, JE, 1988
)
0.27
" We measured FEV1 before and at regular intervals after exposure to TDI and performed dose-response curves to methacholine and bronchoalveolar lavage 8 hr after TDI in two subjects with previously documented late asthmatic reaction; then we repeated the same procedure a few weeks after treatment with steroids."( Importance of airway inflammation for late asthmatic reactions induced by toluene diisocyanate in sensitized subjects.
Boschetto, P; Bruchi, O; Cappellazzo, G; Fabbri, LM; Mapp, CE; Milani, GF; Pivirotto, F; Zocca, E, 1987
)
0.27
" We measured FEV1 before and at regular intervals after exposure to TDI, and performed dose-response curves to methacholine and bronchoalveolar lavage at 8 h after TDI in a group of 6 subjects with late asthmatic reactions and in 6 subjects with only early asthmatic reactions."( Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate.
Boschetto, P; Burlina, A; Fabbri, LM; Licata, B; Mapp, CE; Milani, G; Pivirotto, F; Plebani, M; Zocca, E, 1987
)
0.27
" However, it did not occur in guinea pigs after intranasal instillation (instead of inhalation) and only occurred after oral dosage with TDI when the dose was relatively high."( Specific inhibition of contact sensitivity in the guinea pig following tolylene diisocyanate inhalation.
Doe, JE; Hicks, R; Milburn, GM, 1982
)
0.26
"A four-year longitudinal study of ventilatory function in polyurethane-foam production workers exposed to toluene diisocyanate (TDI) revealed a dose-response relationship between average exposure to TDI and change in forced expiratory volume per second (FEV-1)."( Accelerated loss of FEV- in polyurethane production workers: a four-year prospective study.
Main, DM; Musk, AW; Pagnotto, LD; Wegman, DH, 1982
)
0.26
" These observations are consistent with comparative toxicokinetic studies in rats, which demonstrate significant levels of TDA following oral dosing with TDI--due to the acidic environment in the stomach--but not after inhalation."( Toluene diisocyanate: an assessment of carcinogenic risk following oral and inhalation exposure.
Doe, JE; Hoffmann, HD,
)
0.13
" In conclusion, by altering the exposure time and/or cumulative dosage of TDI different biological reactions can be elicited in exposed mice."( Long-term topical exposure to toluene diisocyanate in mice leads to antibody production and in vivo airway hyperresponsiveness three hours after intranasal challenge.
Buckley, TL; Dormans, J; Garssen, J; Muis, TL; Nijkamp, FP; Scheerens, H; Van Loveren, H, 1999
)
0.3
" Basal ACH dose-response curves, measured twice in intervals of 1 h using tracheal preparations of 11 guinea pigs previously not exposed to IC, were reproducible."( Subchronic exposure to diisocyanates increases guinea pig tracheal smooth muscle responses to acetylcholine.
Baur, X; Marczynski, B; Marek, W; Mensing, T; Potthast, J, 1999
)
0.3
"Uncertainty of the transport of reactive chemicals to the lung is a major concern when using intranasal dosing of animals."( The importance of the diluent for airway transport of toluene diisocyanate following intranasal dosing of mice.
Ebino, K; Karol, MH; Lemus, R, 1999
)
0.3
" Neither cross sectional nor longitudinal analyses of FVC and FEV1 showed significant dose-response findings relative to exposure to TDI across the total exposed population."( Respiratory health surveillance in a toluene di-isocyanate production unit, 1967-97: clinical observations and lung function analyses.
Klees, JE; Ott, MG; Poche, SL, 2000
)
0.31
" The sensitizing capacity of known allergens was quantified by dose-response modeling."( A quantitative method for assessing the sensitizing potency of low molecular weight chemicals using a local lymph node assay: employment of a regression method that includes determination of the uncertainty margins.
de Jong, WH; Slob, W; van Loveren, H; van Och, FM; Vandebriel, RJ, 2000
)
0.31
" Bronchial rings were incubated with normal or immune serum (100 microl ml(-1) for 2 h) and dose-response curves to TDI (0."( Serum-mediated relaxant response to toluene diisocyanate (TDI) in isolated guinea-pig bronchi.
Boschetto, P; Chitano, P; De Marzo, N; Fabbri, LM; Faggian, D; Jovine, L; Mapp, CE; Plebani, M, 2001
)
0.31
" The dosing solutions were known to have degraded, and TDI would hydrolyze to diaminotoluene in the acidic stomach environment."( Toxicology of toluene diisocyanate.
Collins, MA, 2002
)
0.31
" In this study a rat model was used to evaluate the TDI skin absorption to explore the dose-response pattern and to determine the kinetic characteristics of urinary toluene diamine (U-TDA) during skin exposure."( Urinary excretion of toluene diisocyanates in rats following dermal exposure.
Chang, HY; Lin, WC; Shih, TS; Tsai, PJ; Wang, ST; Yeh, HJ, 2008
)
0.35
" Clear dose-response relationships were observed between three different measures of exposure and symptoms of the eyes."( Eye and airway symptoms in low occupational exposure to toluene diisocyanate.
Axmon, A; Broberg, K; Littorin, M; Sennbro, CJ; Tinnerberg, H, 2007
)
0.34
" On day 14, the mice were oropharyngeally dosed with 40 μL of a NP suspension (0."( Lung exposure to nanoparticles modulates an asthmatic response in a mouse model.
Boland, S; De Vooght, V; Dinsdale, D; Hoet, PH; Hussain, S; Luyts, K; Marano, F; Martens, JA; Nemery, B; Thomassen, LC; Vanoirbeek, JA; Verbeken, E, 2011
)
0.37
" The specificity of adjustment was experimentally verified by decreased eNO following inhalation dosing of the non-selective nitric oxide synthase inhibitor amoniguanidine."( Rat models of acute lung injury: exhaled nitric oxide as a sensitive, noninvasive real-time biomarker of prognosis and efficacy of intervention.
Li, W; Liu, F; Pauluhn, J; Trübel, H; Wang, C, 2013
)
0.39
" The Cconst×tvar regimen yielded the most conclusive dose-response relationship as long C was high enough to overcome the scrubbing capacity of the upper airways."( Development of a respiratory sensitization/elicitation protocol of toluene diisocyanate (TDI) in Brown Norway rats to derive an elicitation-based occupational exposure level.
Pauluhn, J, 2014
)
0.4
" Ears of BALB/c mice were dosed once with TDI (0."( Toluene diisocyanate (TDI) disposition and co-localization of immune cells in hair follicles.
Anderson, SE; Beezhold, DH; Green, BJ; Hettick, JM; Long, CM; Nayak, AP; Siegel, PD, 2014
)
0.4
" In workers, we found a dose-response relationship between TDI exposure biomarkers in urine and LPA levels in plasma."( Toluene diisocyanate: Induction of the autotaxin-lysophosphatidic acid axis and its association with airways symptoms.
Axmon, A; Broström, JM; Ghalali, A; Högberg, J; Jönsson, BA; Lindh, CH; Littorin, M; Stenius, U; Tinnerberg, H; Ye, ZW; Zheng, H, 2015
)
0.42
"The literature was reviewed for data suitable for dose-response modeling."( Occupational asthma risk from exposures to toluene diisocyanate: A review and risk assessment.
Daniels, RD, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
haptenAny substance capable of eliciting an immune response only when attached to a large carrier such as a protein. Examples include dinitrophenols; oligosaccharides; peptides; and heavy metals.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
toluene meta-diisocyanateA diisocyanate that consists of toluene bearing two isocyanato functional groups positioned meta to one another.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (36)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency52.01620.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency33.38810.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency42.63300.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency28.18380.000221.22318,912.5098AID588516
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency0.76720.000657.913322,387.1992AID1259394
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency44.43760.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency48.64330.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency28.08850.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency31.55440.001530.607315,848.9004AID1224841; AID1224842; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency58.40740.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.28530.000229.305416,493.5996AID743069; AID743075; AID743077; AID743079
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency56.23410.001019.414170.9645AID588537
aryl hydrocarbon receptorHomo sapiens (human)Potency29.67130.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency58.40740.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency77.36040.039147.5451146.8240AID1224845
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency19.88940.000627.21521,122.0200AID651741; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.00000.00798.23321,122.0200AID2551
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency15.84890.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency37.57800.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency15.84891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)10.00000.00033.166210.0000AID482143
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID482143Agonist activity at human TRPA1 channel expressed in HEK293 cells assessed as increase in intracellular calcium influx2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (872)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990295 (33.83)18.7374
1990's207 (23.74)18.2507
2000's184 (21.10)29.6817
2010's147 (16.86)24.3611
2020's39 (4.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.14 (24.57)
Research Supply Index6.85 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index53.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (1.28%)5.53%
Reviews54 (5.78%)6.00%
Case Studies51 (5.46%)4.05%
Observational0 (0.00%)0.25%
Other817 (87.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]